Navigation Links
Leukemia Drug Proves Safe and Effective Over the Long Term
Date:11/7/2007

WASHINGTON, Nov. 7, /PRNewswire-USNewswire/ -- The drug imatinib mesylate, more commonly known as Gleevec(R), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood, the official journal of the American Society of Hematology.

A team of researchers from the U.S. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years. Prior to enrollment, all study participants had experienced either treatment failure or intolerance with interferon alpha, which was the standard of care for CML at the time the study was initiated.

"The long-term follow-up results of imatinib in CML post interferon failure reassure us of the high efficacy of the drug and its safety," stated Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center. "With a six-year follow-up, the estimated six-year survival rate is 76 percent. In historical data, after interferon failure the average survival was about three to four years."

Imatinib dosage began at 400 milligrams per day and was escalated to 600 mg/d or 800 mg/d in patients who did not achieve positive treatment responses within set time periods or whose disease relapsed.

The best possible treatment outcome -- a complete cytogenetic response, which is the elimination of the genetic abnormality associated with the disease -- occurred in 57 percent of the study participants and was achieved in a median time of eight months. Overall survival rates and avoidance of disease progression were strongly correlated with cytogenetic response by 12 months; those with a minimal or no cytogenetic response within the first year faired poorly.

The incidence of serious side effects was low and, although 15 cases of heart dysfunction were reported in study participants, only four cases were considered to be drug-related. During the study, 35 patients discontinued the drug because of adverse events or abnormal test results.

"About half of the patients on the study continue to receive imatinib and 40 percent are in complete cytogenetic response," said Dr. Kantarjian. "No long-term new toxicities have been observed. In particular, the drug-related cardiac toxicity, which was reported to be of concern last year, was quite rare."

This clinical trial was the basis for the first approval of imatinib for CML, which has since become the standard of care for the disease.

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at http://www.bloodjournal.org.


'/>"/>
SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
8. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... FREMONT, Calif. , March 29, 2017 /PRNewswire/ ... vision for patients as the highest standard in ... Today, Krypton Vision introduces its objective Wavefront-driven refraction ... conventional, subjective approach. This enables an unprecedented level ... optics - exceptional vision relegated to Topgun Navy ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... ... 2017 , ... For many women, getting birth control isn’t as easy as it should be. ... have access to a health care facility or a pharmacy within 60 minutes of where ... States or for many who are faced with health or personal issues that leave them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth ... Congress to protect parental rights and civil liberties, and to restore transparency within ... The demonstration coincides with a press conference taking place Friday morning calling on ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., a ... announce it has joined the National Association for Home Care and Hospice (NAHC), ... disabled, and dying Americans of all ages and the caregiver who provide them ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
Breaking Medicine News(10 mins):